Skip to main content

Table 8 Selected studies for myeloproliferative neoplasm from 2020 ASH annual meeting

From: Novel agents and regimens for hematological malignancies: recent updates from 2020 ASH annual meeting

Abstract #

Authors (references)

Study agents

Phase

NCT No

3442

Kish et al. [74]

Ruxolitinib

Retrospective

N/A

2518

Passamonti et.al. [75]

Ruxolitinib

Retrospective

N/A

1250

Drummond et.al. [77]

Vidaza/Ruxolitinib

1b

ISRCTN 16783472

54

Verstovsek et al. [82]

Momelotinib

Extension Study

N/A

3002

Potluri et.al. [87]

Navitoclax/Rux

III

NCT04472598

1255

Dilley et al. [86]

Navitoclax/Rux

III

NCT04468984

52

Pemmaraju et al. [88]

Navitoclax/Rux

II

N/A

483

Daltro De Oliveira et al. [90]

Interferon-Alpha

N/A

N/A